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(http://creativecommons.org/licenses/by/4.0/).My six-year-old daughter has an extremely rare genetic condition
with too many names. The one I use is M-CM, or macrocephaly-
capillary malformation syndrome (Toriello and Mulliken, 2007).
M-CMwasﬁrst delineated as a syndrome in two papers in 1997, one
from the United Kingdom (Clayton-Smith et al., 1997) and one from the
United States (Moore et al., 1997). The papers were written by clinical
geneticists with dysmorphology expertise who had seen more than
one patient and had identiﬁed a pattern of remarkable features. Prior
to 2012, therewere no known inherited cases, so the conditionwas con-
sidered to be sporadic. Several papers subsequently reﬁned the descrip-
tion of the phenotype and suggested diagnostic criteria (Robertson
et al., 2000; Franceschini et al., 2000;Wright et al., 2009; Martínez-Glez
et al., 2010). In June 2012mosaic PIK3CAmutations were identiﬁed as a
genetic cause for M-CM (Rivière et al., 2012).
My daughter had a difﬁcult and frightening start due to pleural effu-
sion: she was intubated from birth to ten days of age. While still in the
NICU she displayed a richness of observable phenotypic gifts that
could havemade her diagnosis fairly easy had anyonewith appropriate
skills been available to us. She was asymmetrical from her head to her
toes, enormous at 11 lb, yet very weak. Her second and third toes
were joined together on each foot, the majority of her body and part
of her face were covered in reddish birthmarks, and there was a darker
birthmark on her lower lip that gave her a Pierrot-doll appearance.
Finally, she had a sweet button nose that does not run in our family.
I would gradually learn the clinical names for some of these features,
names needed in order toﬁnd a diagnosis: hemihyperplasia,macrosomia,
hypotonia, syndactyly, depressed nasal bridge. The red birthmarks have
unreliable nomenclature, and some might argue that they should not be
called birthmarks at all. Researchers seem to have settled on capillary
malformations, which is a correct descriptor. But they have also been. This is an open access article underreferred to as cutis marmorata telangiectatica congenita, hemangioma,
and cutis marmorata. Some patients do indeed have some of these
other vascular anomalies, but often the terms have been applied
incorrectly.
Living in a Lyme-endemic area gave us an early introduction to the
tendency to gravitate to the familiar. I had gotten sick in the middle of
my pregnancy and was treated for Lyme disease as a precaution. The
ﬁrst theory about my daughter's condition was that it was congenital
Lyme, the very existence ofwhich is controversial. Infectious disease ex-
pertswere contacted, testswere run, and this ideawas dismissed before
we left the NICU at 2.5 weeks.
We next visited a vascular anomalies team composed of surgeons
and dermatologists. The extensive red birthmarks and asymmetry
pointed to the appropriateness of this team. They conﬁdently provided
a diagnosis that had not been published in the medical literature but
was based on their experience of seeing a high volume of patients
with vascular anomalies. We were told that, in spite of her rough start,
our daughter's issues would only be cosmetic. This team did not include
neurologists, whomight have recognized hypotonia and ﬂagged impor-
tant neurological concerns. It also did not include a geneticist, who
might have seen the bigger picture.
This was a very difﬁcult time for us, perhaps the most difﬁcult of my
life. My daughter had hip dysplasia and was so hypotonic and
hypermobile that when the local orthopedist felt the way that her legs
moved, he immediately told us that we needed more specialized care
than he could provide. But becausewe hadbeen told that our daughter's
condition was strictly cosmetic, we couldn't convince our insurance
company that she needed specialized orthopedic care.
Eventually, after a couple of months of making it my full-time job
to obsessively search the internet, I found my daughter's diagnosis. I
did not ﬁnd it in a journal article or a diagnostic algorithm. It was in a
comment of a blog kept by the parent of a baby who looked like my
daughter. That comment led to another blog about a child who wasthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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care doctor to order a brain MRI, which showed correlative brain
ﬁndings. We eventually had the diagnosis conﬁrmed by a local
geneticist, and then by another geneticist who had some expertise
in the condition. This was shortly before the discovery of PIK3CA's in-
volvement in M-CM.
When I look back on this period, knowing what I know now about
genetic conditions and the characteristics of my daughter's syndrome,
the lack of clinical genetics knowledge amongother specialties and gen-
eral pediatricswas stunning.My daughter had anobservable phenotype
that hit the bullseye for her diagnosis, but none of the professionals that
we saw had the training to interpret the signiﬁcance of her features that
fell outside of their specialties, nor even to recognize that a geneticist
might understand a constellation of physical signs and have some talent
other than administering genetic tests. A vague order of “genetic test-
ing” had been given by one of the NICU doctors, but nobody knew spe-
ciﬁcally what to test for — so the order was dropped.
This lack of access to clinical genetics is hardly unique to our story. In
Facebook groups for characteristics that my daughter has (hypotonia
and hemihyperplasia), undiagnosed people regularly share questions
and confusion about whether their condition is a thing unto itself or
part of a larger syndrome. Group participants suggest that they get a ge-
netics referral, which has not been offered by their providers andwhich
is sometimes met with resistance by their current primary care and/or
specialist clinicians. Patients then come back and ask if a ﬁve- to six-
month wait to see genetics is normal, and the support group partici-
pants reply that, unfortunately, it is.
The vastmajority of these interactions between anxious parents and
ill-equipped clinicians involve families seeking care for young children.
Older patients born before the existence of a clinical description are less
likely to come to a genetics clinic. In theM-CM population, for example,
anyone over 18 years of age would have been born before a diagnosis
existed. These patients seem to get diagnosed only if they havemysteri-
ous health problems and a caregiver decides it is worthwhile to engage
in the difﬁcult business of revisiting a diagnosis.
Just like any specialty, patient experiences with clinical genetics
vary, and the role that the geneticist takes on in the patient's care is
not consistent across providers. The reason for this is unclear to me,
but I will share our experience. By the time we visited our ﬁrst geneti-
cist, whowas local to us, I had heard about the experience of other fam-
ilies with M-CM. A small concentration of these people had seen the
same couple of providers, whohad cultivated some expertise in the syn-
drome and published their research and experiences. For these families,
the geneticists followed their children over time and continued to con-
sult on the condition long after the initial diagnosis, providing a sort of
complex primary care. Besides the obvious beneﬁts of ongoing special-
ized consultation for patients, the geneticists could also inform the pa-
tients about the most up-to-date ﬁndings related to the syndrome and
suggest appropriate management.
My family was very excited for our ﬁrst appointment with our local
geneticist, thinking that we were going to meet someone who would
provide ongoing guidance for this bewildering journey that we had
found ourselves on. We were disappointed to ﬁnd that the geneticist
saw his role strictly as a diagnostician. He provided us with a one-
page report with a few paragraphs about managing our daughter's con-
dition for the rest of her life. We never saw him again.
We decided to make the 10-hour drive to see one of the geneticists
whowe knewhad expertise in the syndrome.M-CMhas highly variable
severity across patients, and we wanted a sense of where our infant
daughter ﬁt along that spectrum. This geneticist spent several hours
with us, thoroughly examined our daughter and reviewed her brain
MRIs. He answered all of our questions as best he could —many of the
answers were “we don't know,” which was informative in its own
way. Shortly after we got home from the visit, a 17-page report arrived
that covered every body system known to be affected by M-CM and
suggested appropriate monitoring and management. Now we had adetailed document to provide to other specialists about a condition
that they might see once in their careers, if ever.
The clinical geneticists who provide this level of attention, along
with the ones who originally recognized the phenotypic pattern of the
condition, are the heroes of our M-CM story. Phenotype is really what
we care about as patients and parents.Wewant to knowwhat to expect
and the best way to manage the challenges. We especially want to con-
nectwithpeoplewhoare facing the same speciﬁc issues as us in order to
learn from their experiences.
Unfortunately, the geneticist thatwe traveled to nowworks in a spe-
cialty clinic and is unable to see M-CM patients. At the time, one other
geneticist in the United States had a similar level of clinical experience
and trust from the M-CM patient community, but that geneticist is
also no longer available to patients. It is not unusual for rare disease pa-
tients to have a very limited number of clinical experts to turn to, and if
oneof these experts does notwork out for any reason – such as distance,
insurance coverage, availability, or even personality – patients are on
their own.
Since the genetic cause of M-CM was identiﬁed in 2012, the M-CM
literature has shifted from a focus on case studies with phenotypic
and medical descriptions to one on genomics and genomic testing.
Whilewe recognize the importance of genomic science for reproductive
planning and future therapeutics, from our family's perspective it is
hard to get excited about this shift. The research that affects us most di-
rectly concerns outcomes, optimal care, and management based on the
resources available to us now.
It turns out that M-CM sharesmosaic activatingmutations in PIK3CA
with several other syndromes (Keppler-Noreuil et al., 2014), some of
which have previously gotten more attention from vascular anomalies
specialists than geneticists. These syndromes are now viewed as
existing on a spectrum. The task for geneticists will be to untangle geno-
type–phenotype correlations across the distinct entities. Many patients
have cycled through multiple diagnoses for these various conditions, so
parent and patient advocates were connected and seeing overlap well
before the genetic bases were identiﬁed.
This recognition is a testament to the signiﬁcance of phenotype.
Some patients along the PIK3CA-overgrowth spectrum express confu-
sion when they are told that they may have another of these conditions
instead of their current diagnosis. The only thing distinguishing the con-
ditions right now is phenotype. It's hard for peoplewhomay land on the
margins of a particular OMIM description to understand that a genetic
test cannot currently provide more clarity than a thorough description
of phenotype.
I believe that the best, fastest, and perhaps only way for these condi-
tions to be understood is for patients to be seen in pediatric specialty
clinics that 1) attract a relatively large volumeof patients; and 2) strong-
ly integrate clinical genetics into their practices. I suspect thismay apply
to many other conditions as well, and not necessarily just rare ones. For
example, might obesity clinics discover phenotypic clusters with genet-
ic underpinnings?
In the absence of information available in clinical settings, parents
and patients go online to ﬁnd others facing similar issues (Might and
Wilsey, 2014). We naturally group ourselves according to syndrome
characteristics, and our insights into theways that the groupswe belong
to are affected is generally underappreciated and underutilized by doc-
tors and researchers. Patient families are highly motivated and invested
in building knowledge about their conditions; at the risk of immodesty,
we do an incredible job of it with the tools available to us.
Sequencing genomes is easy. Phenotyping is hard. But if we have any
hope of making progress in understanding M-CM and countless other
rare conditions, researchers must leverage patient communities in
order to do the hard part.
So how canwe raise the stature of phenotype? In publications onmy
daughter's condition, the phenotype is usually nomore than a short list
of features, or the written-out words of the acronym used to name the
condition. I read a paper recently with exquisitely detailed phenotypic
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gated to the supplement, i.e., it was not thought to be important enough
to include in the main body of the paper.
As the Precision Medicine Initiative™ ramps up and deﬁnes itself,
the problem of phenotyping poses a daunting challenge. Rare diseases
make strong cases for developing phenotyping methods that can be
married to the computational outcomes of genomic evaluation. This
needs to be done without steamrolling the human interactions in the
clinic that are required for effective patient care and research. Rare dis-
ease patient families will be eager and valuable partners in this effort if
given the opportunity.
Given that our medical system currently seems unable to provide
sufﬁcient genetics professionals for patients to be seen in a timely man-
ner, other front-line doctors will need better diagnostic and observa-
tional skills, and awareness of how the pieces of a diagnostic puzzle
may lie outside of their specialty. It will be unfortunate if in the clinic,
as in the literature, a shift toward genetic sequencing and analysis
comes at the expense of skill and interest in clinical phenotyping.
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